Clinical landscape of TP73 structural variants in ATL patients

Hiroaki Hiramatsu; Rui Yokomori; Liu Shengyi; Norio Tanaka; Seiichi Mori; Kazuma Kiyotani; Osamu Gotoh; Shigeru Kusumoto; Nobuaki Nakano; Youko Suehiro; Asahi Ito; Ilseung Choi; Eiichi Ohtsuka; Michihiro Hidaka; Kisato Nosaka; Makoto Yoshimitsu; Yoshitaka Imaizumi; Shinsuke Iida; Atae Utsunomiya; Tetsuo Noda; Hiroyoshi Nishikawa; Ryuzo Ueda; Takaomi Sanda; Takashi Ishida

doi:10.1038/s41375-023-02059-9

Clinical landscape of TP73 structural variants in ATL patients

Leukemia. 2023 Dec;37(12):2502-2506. doi: 10.1038/s41375-023-02059-9. Epub 2023 Oct 20.

Authors

Hiroaki Hiramatsu¹, Rui Yokomori², Liu Shengyi¹, Norio Tanaka³, Seiichi Mori³, Kazuma Kiyotani⁴, Osamu Gotoh³, Shigeru Kusumoto⁵, Nobuaki Nakano⁶, Youko Suehiro^{7

8}, Asahi Ito⁵, Ilseung Choi⁷, Eiichi Ohtsuka⁹, Michihiro Hidaka¹⁰, Kisato Nosaka¹¹, Makoto Yoshimitsu¹², Yoshitaka Imaizumi¹³, Shinsuke Iida⁵, Atae Utsunomiya⁶, Tetsuo Noda¹⁴, Hiroyoshi Nishikawa^{1

15}, Ryuzo Ueda¹, Takaomi Sanda^{16

17

18}, Takashi Ishida^{19

20}

Affiliations

¹ Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
² Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
³ Project for Development of Innovative Research on Cancer Therapeutics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
⁴ Project for Immunogenomics, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, Tokyo, Japan.
⁵ Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
⁶ Department of Hematology, Imamura General Hospital, Kagoshima, Japan.
⁷ Department of Hematology, National Hospital Organization Kyushu Cancer Centre, Fukuoka, Japan.
⁸ Department of Cell Therapy, National Hospital Organization Kyushu Cancer Centre, Fukuoka, Japan.
⁹ Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
¹⁰ Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.
¹¹ Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan.
¹² Department of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
¹³ Department of Hematology, Nagasaki University Hospital, Nagasakin, Japan.
¹⁴ Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
¹⁵ Division of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, Japan.
¹⁶ Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. csitakao@nus.edu.sg.
¹⁷ Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. csitakao@nus.edu.sg.
¹⁸ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. csitakao@nus.edu.sg.
¹⁹ Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan. itakashi@med.nagoya-u.ac.jp.
²⁰ Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. itakashi@med.nagoya-u.ac.jp.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Letter

MeSH terms

Cell Line, Tumor
Cell Proliferation
Gene Expression Regulation, Neoplastic
Genes, Tumor Suppressor
Humans
MicroRNAs*
RNA, Long Noncoding*
Tumor Protein p73 / genetics

Substances

Tumor Protein p73
RNA, Long Noncoding
MicroRNAs

Publication types

MeSH terms

Substances

Grants and funding